Sigma-Tau Pharmaceuticals Offers New Co-Pay Assistance Program for Adagen® Patients
10/9/2012 9:12:49 AM
GAITHERSBURG, Md., Oct. 9, 2012 (GLOBE NEWSWIRE) -- Continuing its dedication to those patients impacted by rare diseases, today Sigma-Tau Pharmaceuticals, Inc. announced that it will expand its current patient assistance program to provide financial assistance for patients within the United States who are prescribed ADAGEN® (pegademase bovine)Injection for adenosine deaminase-severe combined immunodeficiency disease (ADA-SCID). The Company's new Co-Pay Assistance Program will cover all fees associated with co-pays incurred by eligible ADAGEN® patients. ADAGEN® is the only commercially approved enzyme replacement therapy available to treat ADA-SCID patients.